Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors für adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Swizerland
Sprache des Titels:
Englisch
Journal:
Journal of European Academy of Dermatology and Venerology